Abstracts tagged "pathogenesis"

Abstract Number: 2578 • 2016 ACR/ARHP Annual Meeting
Plasma Levels of Bone Morphogenetic Protein (BMP) Subgroups and Their Inhibitors (noggin, sclerostin) in Rheumatoid Arthritis Patients and Correlation with Disease Activity, Clinical and Radiographic Progression
Ozge Kockara¹, Merve Sibel Gungoren², Erdem Karabulut³, Sebnem Ataman⁴ and Filiz Akbiyik², ¹Physical Medicine and Rehabilitation, Ankara University Faculty of Medicine, Ankara, Turkey, ²Medical Biochemistry, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Biostatistics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁴Rheumatology Department, Ankara University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Progressive bone destruction occurs in rheumatoid arthritis (RA) due to imbalance of osteoblast/osteoclast activity. Bone morphogenetic proteins (BMPs) regenerate bone damage by stimulating the…
Abstract Number: 570 • 2016 ACR/ARHP Annual Meeting
A Molecular Timeline for Preclinical RA Pathogenesis Defined By Dysregulated PTPN22, Hypercitrullination, and Aberrant Cytokine/Metabolic Profiles in PBMC of at-Risk Individuals
Hui-Hsin Chang¹, Nishant Dwivedi², Bo Sun², Deepak A. Rao³, Jeffrey A. Sparks³, Jennifer Kinslow⁴, Yuko Okamoto⁴, Kevin D. Deane⁵, M. Kristen Demoruelle⁶, Jill M. Norris⁷, Elizabeth Karlson², V. Michael Holers⁸ and I-Cheng Ho¹, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴University of Colorado School of Medicine, Aurora, CO, ⁵Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁶Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁷Epidemiology, Colorado School of Public Health, Aurora, CO, ⁸Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: One unique feature of RA is the presence of ACPA. PTPN22 is a phosphatase that also acts to suppress citrullination independently of its phosphatase…
Abstract Number: 2928 • 2016 ACR/ARHP Annual Meeting
Hypomethylation of an Intragenic Alternative Promoter Contributes to Impaired Treg Function in Rheumatoid Arthritis By Transcriptional Interference with Expression of the Treg-Specific Protein, Glycoprotein a Repetitions Predominant (GARP)
Alla Skapenko, Jan Leipe and Hendrik Schulze-Koops, Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany
Background/Purpose: The expression of Treg specific genes, such as the master transcription factor of Tregs, FoxP3 or the Treg specific surface molecule, glycoprotein A repetitions…
Abstract Number: 581 • 2016 ACR/ARHP Annual Meeting
Cell-Mediated Neutrophil Lysis-a Mechanism Promoting Hypercitrullination in Rheumatoid Arthritis?
Tal Gazitt¹, Christian Lood¹, Xizhang Sun², David Feith³, Jeffrey Ledbetter², Gordon Starkebaum¹, Thomas Loughran Jr.⁴ and Keith B. Elkon¹, ¹Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, ²University of Washington, Seattle, WA, ³Hematology and Oncology, University of Virginia, Charlottesville, VA, ⁴Hematology Oncology, University of Virginia, Charlottesville, VA
BACKGROUND/PURPOSE:Protein citrullination, the post-translational conversion of arginine to citrulline, mediated by peptidylarginine deiminase (PAD) enzymes, is considered a likely mechanism for the stimulation of anti-citrullinated…
Abstract Number: 3017 • 2016 ACR/ARHP Annual Meeting
Elevated Neutrophil Extracellular Trap Levels Correlate with Anti-CCP3-IgG and Anti-CCP3-IgA Levels in the Sputum of Individuals at-Risk for Future Rheumatoid Arthritis
M. Kristen Demoruelle¹, Monica Purmalek², Heather Rothfuss³, Michael Weisman⁴, Lindsay Kelmenson¹, Michael Mahler⁵, Jill M. Norris⁶, Brian Cherrington³, Mariana Kaplan², V. Michael Holers¹ and Kevin D. Deane¹, ¹Rheumatology Division, University of Colorado Denver, Aurora, CO, ²Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Zoology and Physiology, University of Wyoming, Laramie, WY, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Research and Development, Inova Diagnostics, San Diego, CA, ⁶Epidemiology, Colorado School of Public Health, Aurora, CO
Background/Purpose: The initial site of anti-citrullinated protein antibody (ACPA) generation in RA has been proposed to be a mucosal site. We have previously demonstrated ACPA…
Abstract Number: 584 • 2016 ACR/ARHP Annual Meeting
Glycoprotein VI: A Potential Target for ACPA-Mediated Platelet Activation?
John Stack¹, Anne Madigan², Laura Helbert¹, Niamh Redmond¹, Eimear Dunne³, Dermot Kenny³ and Geraldine M. McCarthy², ¹Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ²Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ³Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland
Background/Purpose: Arterial thrombosis is a major cause of mortality in rheumatoid arthritis (RA),especially in anti-citrullinated protein antibody (ACPA)-positive patients Recent studies suggest that platelet activation…
Abstract Number: 3019 • 2016 ACR/ARHP Annual Meeting
Sputum Antibodies to Individual Citrullinated Protein/Peptide Antigens Are Elevated in Subjects at-Risk of Future RA and Subjects with Established Disease
Emily Bowers¹, M. Kristen Demoruelle², Michael Weisman³, Jill M. Norris⁴, William H. Robinson⁵, V. Michael Holers² and Kevin D. Deane², ¹Medicine, University of Colorado Denver, Aurora, CO, ²Rheumatology Division, University of Colorado Denver, Aurora, CO, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Epidemiology, Colorado School of Public Health, Aurora, CO, ⁵Stanford University School of Medicine, Stanford, CA
Background/Purpose: Multiple studies demonstrate that ACPAs are elevated in the serum years prior to the onset of seropositive RA during a preclinical period of autoimmunity.…
Abstract Number: 988 • 2016 ACR/ARHP Annual Meeting
Risk of Rheumatoid Arthritis after Transfusion of Blood from Donors Later Diagnosed with Rheumatoid Arthritis: A Retrospective Cohort Study
Søren Andreas Just¹, Kjell Titlestad², Gustaf Edgren³, Klaus Rostgaard⁴, Johan Askling⁵, Hanne Lindegaard¹ and Henrik Hjalgrim⁴, ¹Department of Rheumatology, Department of Rheumatology, Odense University Hospital, Odense, Denmark, Odense, Denmark, ²Department of Clinical Immunology, Department of Clinical Immunology, Odense Unversity Hospital, Odense, Denmark, Odense, Denmark, ³Department of Medical Epidemiology and Biostatistics, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁴Epidemiology Research, Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark, Copenhagen, Denmark, ⁵Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Rheumatoid Arthritis (RA) is a disease that can have a long sub-clinical phase. During this phase the person with pre-RA could have factors in…
Abstract Number: 3022 • 2016 ACR/ARHP Annual Meeting
Autoantibodies to Peptidylarginine Deiminase 2 Protect Against Radiographic Progression in Patients with Rheumatoid Arthritis
Erika Darrah¹, Jon T. Giles², Ryan Davis¹, Pooja Naik¹, Maximilian Konig¹ and Felipe Andrade¹, ¹Department of Medicine, Division of Rheumatology, The Johns Hopkins University, Division of Rheumatology, Baltimore, MD, ²Columbia University, College of Physicians and Surgeons, Division of Rheumatology, New York, NY
Background/Purpose: The mechanisms that drive clinical heterogeneity and outcomes in patients with rheumatoid arthritis (RA) are poorly understood, but precise biomarkers may identify clinically unique…
Abstract Number: 1040 • 2016 ACR/ARHP Annual Meeting
Stressful Life Events : A Trigger for Rheumatoid Arthritis Onset within a Year. a Case-Control Study
Jimmy Gross¹, Nadia Oubaya^2,3, Florent Eymard¹, Alexia Hourdille¹, Xavier Chevalier¹ and Sandra Guignard¹, ¹Department of Rheumatology, APHP Henri Mondor hospital, Créteil, France, ²Public Health Department, F-94000, APHP Henri Mondor hospital, Créteil, France, ³DHU A-TVB, IMRB- EA 7376 CEpiA (Clinical Epidemiology And Ageing Unit), F-94000, Université Paris-Est, UPEC,, Créteil, France
Background/Purpose: To assess the association between recent stressful life events and rheumatoid arthritis (RA) onset. Methods: We conducted a monocentric case-control study of in and…
Abstract Number: 3217 • 2016 ACR/ARHP Annual Meeting
Broad-Based Interrogation of the Serum Proteome Suggests That RA Onset Is Associated with Activation of the Intrinsic Coagulation Cascade
Liam O'Neil¹, Xiaobo Meng², Irene Smolik³, Carol Hitchon² and Hani El-Gabalawy⁴, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba Arthritis Center, Winnipeg, MB, Canada
Background/Purpose: The establishment of longitudinal pre-clinical RA cohorts is beginning to provide important insights into the mechanisms that precede the onset of clinically detectable disease.…
Abstract Number: 1111 • 2016 ACR/ARHP Annual Meeting
Huntingtin Interactin Protein 1 (HIP1) Regulates Receptor Tyrosine Kinases Mediated Activity and Cell Invasiness in Fibroblast-like Synoviocytes
Teresina Laragione, Nasim Azizgolshani, Carolyn Harris, Erjing Gao and Percio Gulko, Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Huntingtin-interacting protein 1 (Hip1) is a new arthritis severity gene recently identified in the Pristane and Collagen-induced arthritis (PIA, CIA) quantitative trait locus Cia25/Pia42…
Abstract Number: 1207 • 2016 ACR/ARHP Annual Meeting
Design of a Multiplex Serum Proteome Assay to Monitor Biologic Drug Response in Rheumatoid Arthritis Patients
Niamh Callan¹, Aisha Butt¹, Stephen R. Pennington², Cathy McGeough³, Philip Gardiner⁴, Gary Wright⁵, Tony Bjourson³ and David S. Gibson⁶, ¹Proteome Research Centre, Conway Institute, University College Dublin, Dublin, Ireland, ²Proteome Research Centre, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, ³Northern Ireland Centre for Stratified Medicine, Ulster University, Londonderry, United Kingdom, ⁴Rheumatology, Altnagelvin Hospital, Londonderry, United Kingdom, ⁵Rheumatology, Musgrave Park Hospital, BELFAST, United Kingdom, ⁶Inflammatory Disease Research Group, Northern ireland Centre for Stratified Medicine, Ulster University, Londonderry, United Kingdom
Background/Purpose: Biologic drugs have revolutionised the treatment of Rheumatoid Arthritis (RA), however these therapies are expensive and exhibit a high non–response rate (30%). Currently there…
Abstract Number: 1213 • 2016 ACR/ARHP Annual Meeting
Targeted Next-Generation Sequencing of 128 Genes Associated with Rheumatoid Arthritis
Khai Pang Leong¹, Liuh Ling Goh², Edward Yu Wing Chee², Petrina Pei Qin Lim², Grace Li-Xian Toh², Ee Tzun Koh³ and Tan Tock Seng Hospital Rheumatoid Arthritis Study Group, ¹Rheumatology/Allerg/Immunology, Tan Tock Seng Hospital, Singapore, Singapore, ²Clinical Research & Innovation Office, Tan Tock Seng Hospital, Singapore, Singapore, ³Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore
Background/Purpose: Through genome-wide association scans (GWAS), more than 120 genes have been found to be associated with rheumatoid arthritis (RA). This study aims to search…
Abstract Number: 1247 • 2016 ACR/ARHP Annual Meeting
Diagnostic Modeling of Rheumatoid Arthritis in Oklahoma Tribal Members Using Soluble Mediators
Lucas Adams¹, Carla J. Guthridge¹, Tim Gross¹, Hua Chen¹, Krista M. Bean¹, Virginia C. Roberts¹, Julie M. Robertson², Melissa E. Munroe¹, Joel M. Guthridge³, Roger Montgomery⁴, M. Sohail Khan⁴, Fabio Mota⁵, Michael Peercy⁶, Bobby Saunkeah⁷ and Judith A. James^8,9, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Acelity, San Antonio, TX, ³Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Cherokee Nation Health Services, Tahlequah, OK, ⁵Chickasaw Nation Medical Center, Ada, OK, ⁶Epidemiology, Chickasaw Nation Department of Health, Ada, OK, ⁷Chickasaw Nation Department of Health, Ada, OK, ⁸Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Diagnosis of RA is difficult in American Indian (AI) patients who often have atypical autoantibodies (e.g. ANA) with erosive arthritis. Soluble mediators may serve…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.